3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Lymphoid
1
Head & Neck
1
Gastrointestinal
1
Breast
1
Conditions
Melanoma
9
Neoplasms
7
Neoplasm Metastasis
7
Carcinoma, Non-Small-Cell Lung
7
Triple Negative Breast Neoplasms
6
Pancreatic Neoplasms
6
Colorectal Neoplasms
5
Lymphoma
4
Liver Neoplasms
4
Lung Neoplasms
3
Kidney Neoplasms
3
Esophageal Neoplasms
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Nasopharyngeal Carcinoma
2
Multiple Myeloma
2
Mesothelioma
2
Locally Advanced Rectal Cancer
2
Hematologic Diseases
2
Esophageal Squamous Cell Carcinoma
2
Colonic Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Renal Cell
2
Adenocarcinoma
2
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Solid Tumor, Adult
1
Interventions
Cisplatin
33
Radiotherapy
23
Cetuximab
18
Paclitaxel
14
Docetaxel
14
pembrolizumab
13
Carboplatin
12
Fluorouracil
10
Radiotherapy, Intensity-Modulated
8
Nivolumab
8
Drug Therapy
7
Erlotinib Hydrochloride
6
Panitumumab
5
dacomitinib
4
Radiation
4
Methotrexate
4
Esophagectomy
4
130-nm albumin-bound paclitaxel
4
durvalumab
3
ON 01910
3
Leucovorin
3
Gemcitabine
3
Chemoradiotherapy
3
vandetanib
2
palbociclib
2
osimertinib
2
nedaplatin
2
fludarabine
2
cabazitaxel
2
atezolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Squamous Cell
×
spartalizumab
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts